StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report released on Monday. The firm issued a hold rating on the stock.

A number of other analysts have also recently commented on the stock. Lake Street Capital cut their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. HC Wainwright reduced their price target on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a report on Tuesday, October 29th.

Ekso Bionics Stock Performance

Ekso Bionics stock opened at $0.77 on Monday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The firm has a 50-day moving average of $1.05 and a 200-day moving average of $1.12. The company has a market cap of $16.92 million, a price-to-earnings ratio of -1.18 and a beta of 1.47. Ekso Bionics has a one year low of $0.74 and a one year high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $6.00 million. During the same period last year, the company posted ($0.24) earnings per share. On average, equities analysts expect that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Institutional Trading of Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC raised its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. 6.42% of the stock is currently owned by institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.